David Rind, ICER CMO

Up­dat­ed: ICER on Alzheimer's: lecanemab should be priced low­er than Aduhelm

Drug pric­ing watch­dog ICER said that the un­cer­tain­ty in the health ben­e­fits of two po­ten­tial Alzheimer’s drugs makes it chal­leng­ing to as­sess their fu­ture cost-ef­fec­tive­ness, ac­cord­ing to a draft re­port re­leased Thurs­day morn­ing.

The re­port eval­u­ates Bio­gen and Ei­sai’s lecanemab and Eli Lil­ly’s do­nanemab, both of which are amy­loid-clear­ing an­ti­body drugs due for FDA de­ci­sions in the com­ing weeks and months. The FDA’s dead­line for a de­ci­sion on lecanemab’s ac­cel­er­at­ed ap­proval is Jan. 6, while the dead­line for do­nanemab is es­ti­mat­ed to be in Feb­ru­ary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.